Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Alumis Inc. Common StockNASDAQ: ALMS
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity falls 6.8% from a year ago
Total equity stood at $452.16M at the end of Q2 FY2026, down 6.8% from a year earlier and down 20.3% from the prior quarter.
Context
- Total equity amounted to 80.7% of total assets at the end of Q2 FY2026, up 1.2 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -6.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 301.3M USD
- Year-over-year change
- +15.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 301.3M | +15.8% |
| FY2024 | 2024-12-31 | 260.1M | +176.7% |
| FY2023 | 2023-12-31 | (339.26M) | -73.8% |
| FY2022 | 2022-12-31 | (195.24M) | — |
Total Equity vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.8% is the 3rd highest of 9, against a peer median of -45.9%.
- Total equity amounts to 80.7% of total assets for ALMS, versus a peer median of 72.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $452.16M USD | -6.8% | — | 80.7% |
| Mar 2026 | $399.9M USD | +2053.8% | — | 79.2% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €146.93M EUR | — | — | 88.7% |
| Mar 2026 | $143.65M USD | -0.3% | -19.5% | 72.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $87.85M USD | -48.0% | — | 82.9% |
| Mar 2026 | $68.32M USD | -44.3% | — | 68.4% | |
| Mar 2026 | $42.16M USD | -33.7% | -33.6% | 63.4% | |
| Mar 2026 | €36.93M EUR | -47.6% | -22.2% | 75.5% | |
| Mar 2026 | $12.75M USD | -62.5% | -47.8% | 3.9% | |
| Dec 2025 | $52K USD | -98.7% | -86.1% | 0.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -45.9% | -33.6% | 72.3% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.